natgillin/translations-raw huggingface dataset:
What is Avonex and what is it used for? 
Kaj je zdravilo Avonex in za kaj se uporablja?
What are the risks associated with Avonex? 
Kakšna tveganja so povezana z zdravilom Avonex?
The exact way that Avonex works in MS is not yet known but the active substance, interferon beta-1a, seems to calm down the immune system, and prevents relapses of MS. 
Natančen način delovanja zdravila Avonex pri multipli sklerozi še ni popolnoma znan, vendar se zdi, da učinkovina, interferon beta-1a, pomirja imunski sistem in preprečuje realpse multiple skleroze.
After two years, 22% of the patients who were treated with Avonex and 35% of the patients treated with placebo had a worsening of disability. 
Po dveh letih se je prizadetost poslabšala pri 22 % bolnikov, ki so se zdravili z zdravilom Avonex, in 35 % bolnikov, ki so prejemali placebo.
Avonex treatment should be stopped in patients who develop progressive (worsening) MS. 
Zdravljenje z zdravilom Avonex je treba prekiniti pri bolnikih, pri katerih se je razvila progresivna (napredujoča) multipla skleroza.
Patients can inject Avonex themselves once they have been trained. 
Bolniki si lahko po ustreznem usposabljanju zdravilo Avonex injicirajo sami.
Avonex is available as a solution for injection in a pre-filled syringe or pre-filled pen. 
Zdravilo Avonex je na voljo v obliki raztopine za injiciranje v napolnjeni injekcijski brizgi ali napolnjenem injekcijskem peresniku.
However, it presented information from published studies on the use of Avonex in patients aged between 12 and 18 years, which showed that they had a decrease in the rate of relapse, possibly due to Avonex treatment. 
Podjetje ni izvedlo nobenih uradnih študij pri bolnikih, mlajših od 16 let, je pa predstavilo informacije iz objavljenih študij uporabe zdravila Avonex pri bolnikih, starih od 12 do 18 let, ki so pokazale, da se je stopnja relapsov, morda zaradi zdravljenja z zdravilom Avonex, zmanjšala.
Avonex can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of MS. 
Predpisovanje in izdaja zdravila Avonex je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem multiple skleroze.
For the full list of side effects and restrictions with Avonex, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Avonex glejte navodilo za uporabo.
Avonex contains the active substance interferon beta-1a. 
Zdravilo Avonex vsebuje učinkovino interferon beta-1a.
The first study involved 301 patients aged 16 years and older with relapsing MS who had experienced at least two relapses in the previous three years or at least one relapse per year if they had had the disease for less than three years. 
Ti bolniki so v preteklih treh letih doživeli vsaj dva relapsa ali vsaj en relaps na leto, če so bili bolni manj kot tri leta.
It is used when the patient is considered to be at high risk of developing MS. Before using Avonex, doctors need to exclude other causes for the symptoms. 
Pred uporabo zdravila Avonex morajo zdravniki izključiti druge možne vzroke za simptome.
A painkiller that prevents fever can be given before each injection and for 24 hours after injection to reduce the flu-like symptoms that may occur during the first few months of treatment. 
Da bi zmanjšali gripi podobne simptome, ki se lahko pojavijo v prvih mesecih zdravljenja, lahko bolnik pred injiciranjem in 24 ur po njem dobi zdravilo proti bolečinam, ki preprečuje povišano telesno temperaturo.
How is Avonex used? 
Kako se zdravilo Avonex uporablja?
How does Avonex work? 
Kako zdravilo Avonex deluje?
Both the Chennai site and the Coimbatore site follow the same provisions. 
Na obeh lokacijah, Chennai in Coimbatore, so upoštevali ista določila.
• The Committee reviewed all available data and information provided by the MAHs/applicants, as well as information provided by Micro Therapeutic Research Labs Limited; 
• odbor je pregledal vse razpoložljive podatke in informacije, ki so jih zagotovili imetniki dovoljenj za promet z zdravilom/predlagatelji, ter informacije, ki jih je predložila družba Micro Therapeutic Research Labs Limited;
Micro Therapeutic Research Labs Ltd is a contract research organisation (CRO) which conducts the analytical and clinical parts of bioequivalence studies, some of which have been used to support marketing authorisation applications of medicines in the EU. 
Družba Micro Therapeutic Research Labs Ltd je pogodbena raziskovalna organizacija, ki izvaja analitski in klinični del študij biološke enakovrednosti, od katerih so se nekatere uporabile v podporo vlogam za pridobitev dovoljenja za promet z zdravili v EU.
Data from bioequivalence studies submitted to the Competent Authorities to demonstrate bioequivalence of medicinal products with their originator is considered unreliable. 
Podatki iz študij biološke enakovrednosti, predložene pristojnim oblastem kot dokaz biološke enakovrednosti zdravil z originatorskim zdravilom, veljajo za nezanesljive.
Therefore, for those products bioequivalence is not established. 
To pomeni, da za vsa ta zdravila biološka enakovrednost ni bila dokazana.
Based on the submitted data during the procedure, the medicinal products Tadalafil Mylan 2.5 mg, 5 mg, 10 mg and 20 mg; Paracetamol DAWA 1000 mg film-coated tablets; Memantine Pharmascope 10 mg and 20 mg; Memantine DAWA 10 mg and 20 mg; Morysa 10 mg and 20 mg - SVUS Pharma a.s.; Bendroflumetiazid Alternova 2.5 mg and 5 mg tablets; the CHMP concluded that bioequivalence has been demonstrated vis-à-vis the EU reference medicinal product and recommended the maintenance of these marketing authorisations. 
Na podlagi predloženih podatkov med postopkom je odbor CHMP presodil, da je bila za zdravila Tadalafil Mylan 2,5 mg, 5 mg, 10 mg in 20 mg; Paracetamol DAWA 1000 mg filmsko obložene tablete; Memantine Pharmascope 10 mg in 20 mg; Memantine DAWA 10 mg in 20 mg; Morysa 10 mg in 20 mg - SVUS Pharma a.s.
The CHMP was requested in particular to provide its opinion under Article 31 of Directive 2001/83/EC as to whether marketing authorisations of these products should be maintained, varied, suspended, or revoked and whether marketing authorisations applications should be authorised. 
Odbor CHMP je bil zlasti zaprošen, naj v skladu s členom 31 Direktive 2001/83/ES poda svoje mnenje o tem, ali naj se dovoljenja za promet s temi zdravili ohranijo, spremenijo, začasno prekličejo ali ukinejo in ali naj se vloge za pridobitev dovoljenj za promet odobrijo.
− Marketing authorisation applications for which no alternative data or a justification was submitted. 
− vloge za pridobitev dovoljenja za promet z zdravilom, za katere niso bili predloženi drugi možni podatki ali utemeljitev.
The findings of the Austrian and Dutch inspections raise serious concerns relating to the suitability of the quality management system in place at Micro Therapeutics Research LTd, India. 
Ugotovitve inšpekcijskih pregledov avstrijskega in nizozemskega organa so vzbudile resne pomisleke o primernosti sistema upravljanja kakovosti v družbi Micro Therapeutics Research LTd v Indiji.
• The Committee considered the procedure under Article 31 of Directive 2001/83/EC for marketing authorisations and marketing authorisation applications for medicinal products for which the clinical and/or bioanalytical parts of the bioequivalence studies were performed at Micro Therapeutic Research Labs Limited during the period between June 2012 and June 2016; 
• odbor je obravnaval napotitev v skladu s členom 31 Direktive 2001/83/ES za dovoljenja za promet z zdravilom in vloge za pridobitev dovoljenja za promet z zdravilom za zdravila, za katera so bili klinični in/ali bioanalitski deli študij biološke enakovrednosti opravljeni v družbi Micro Therapeutic Research Labs Limited v obdobju med junijem 2012 in junijem 2016;
This period of deferral shall not exceed twenty-four months from the Commission Decision. 
Ta odlog je mogoč za obdobje največ štiriindvajsetih mesecev od izdaje sklepa Komisije.
Furthermore, the Committee recommends that the concerned marketing authorisations should be suspended unless the medicinal product is considered critical by the relevant national competent authorities. 
Poleg tega odbor priporoča, da se zadevna dovoljenja za promet z zdravilom začasno umaknejo, razen če je zdravilo po mnenju ustreznega nacionalnega pristojnega organa kritičnega pomena.
In view of the critical inspection findings and the necessity to protect public health in the EU, several Member States considered that it is in the interest of the Union to refer the matter to the CHMP and request that it assesses the impact of the findings mentioned above on the benefit-risk balance of the medicinal products which have been authorised by the Member States on the basis of relevant trials performed at these sites between June 2012 and June 2016 and also that of pending marketing authorisation applications (MAA) that include such studies. 
Glede na ugotovljene kritične ugotovitve in nujnost zaščite javnega zdravja v EU je več držav članic menilo, da je v interesu Unije napotitev zadeve na odbor CHMP, zato so odbor zaprosili, da oceni vpliv zgoraj omenjenih ugotovitev na razmerje med tveganji in koristmi zdravil, ki so jih države članice odobrile na podlagi zadevnih preskušanj, izvedenih na teh lokacijah med junijem 2012 in junijem 2016, ter še nezaključenih vlog za pridobitev dovoljenja za promet, ki vključujejo te študije.
In addition, a study performed at the Micro Therapeutic Research Labs Pvt. Ltd site in Coimbatore was inspected. 
Poleg tega so preučili tudi študijo, izvedeno na lokaciji družbe Micro Therapeutic Research Labs Pvt. Ltd v Coimbatoreju.
For marketing authorisations of a medicinal product considered critical, the suspension may be deferred in the relevant EU Member States for a period which shall not exceed twenty-four (24) months from the Commission Decision. 
Za dovoljenja za promet z zdravilom, ki šteje za zdravilo kritičnega pomena, se lahko začasni umik v zadevni državi članici EU odloži za obdobje največ štiriindvajsetih (24) mesecev od izdaje sklepa Komisije.
Grounds for CHMP opinion Whereas, 
Podlaga za mnenje odbora CHMP
Critical findings were identified following inspections to check compliance with Good clinical practice (GCP) by the Austrian Federal Office for Safety in Healthcare (BASG) and the Health Care Inspectorate of the Netherlands (IGZ) in February 2016 at Micro Therapeutic Research Labs Pvt. Ltd, Chennai, India. 
Z inšpekcijskim pregledom preverjanja skladnosti z dobro klinično prakso, ki sta ga opravila avstrijski zvezni urad za varnost v zdravstvu (BASG) in nizozemski zdravstveni inšpektorat (IGZ) februarja 2016 v družbi Micro Therapeutic Research Labs Pvt. Ltd, Chennai, v Indiji, so prišli do kritičnih ugotovitev.
The CHMP therefore recommended the suspension of the marketing authorisations for all remaining medicinal products concerned by this referral procedure, as bioequivalence vis-à-vis the EU reference medicinal products has not been demonstrated. 
Odbor CHMP je zato priporočil začasen umik dovoljenj za promet z vsemi preostalimi zdravili, ki jih zadeva ta napotitveni postopek, saj biološka enakovrednost z referenčnimi zdravili, odobrenimi v EU, ni bila dokazana.
Where on the basis of these criteria the relevant national competent authorities of the EU Member States consider that a medicinal product is critical, the suspension of the concerned marketing authorisation(s) may be deferred by the period for which the medicinal product is considered critical. 
Če na podlagi teh meril ustrezni nacionalni pristojni organi držav članic menijo, da je zdravilo kritičnega pomena, se lahko začasni umik zadevnih dovoljenj za promet z zdravilom odloži za obdobje, v katerem se zdravilo šteje za zdravilo kritičnega pomena.
For the Hydrokortison Alternova (Orifarm) and Hydrokortison BBS marketing authorisation applications, the CHMP concluded that the Member State(s) will have to consider whether the bridging between the proposed product and the medicinal products described in the literature as par Annex I of Directive 2001/83/EC is sufficiently established as the applications relate to Article 10a of Directive 2001/83/EC (‘Well-established use'). 
Glede vlog za pridobitev dovoljenja za promet z zdraviloma Hydrokortison Alternova (Orifarm) in Hydrokortison BBS je odbor CHMP zaključil, da bodo morale države članice same presoditi, ali je premostitev med predlaganim zdravilom in zdravilom, opisanim v literaturi, v skladu s Prilogo I Direktive 2001/83/ES zadostno vzpostavljena, saj se vloge nanašajo na člen 10a Direktive 2001/83/ES („dobro uveljavljena medicinska uporaba“).
In the absence of the demonstration of bioequivalence vis-à-vis the EU reference medicinal product, the requirements of Article 10 of Directive 2001/83/EC cannot be considered fulfilled, the efficacy and safety of the concerned medicinal products cannot be established, hence the benefit-risk balance cannot be considered positive. 
Ker biološka enakovrednost z referenčnim zdravilom, odobrenim v EU, ni bila dokazana, zahteve člena 10 Direktive 2001/83/ES niso v celoti izpolnjene, varnosti in učinkovitosti zadevnih zdravil pa ni mogoče ugotoviti, zato razmerje med tveganji in koristmi teh zdravil ne more biti pozitivno.
d. Bioequivalence vis-à-vis a valid EU reference medicinal product has been established for marketing authorisation applications listed in Annex Ia of the CHMP Opinion. 
d. Biološka enakovrednost z veljavnim referenčnim zdravilom, odobrenim v EU, je bila ugotovljena za vloge za pridobitev dovoljenja za promet z zdravilom, navedene v Prilogi Ia k mnenju odbora CHMP.
− Authorised medicinal products for which alternative data or a justification was submitted but considered insufficient by the CHMP to establish bioequivalence vis-à-vis the EU reference medicinal product; 
− odobrena zdravila, za katera so bili predloženi drugi možni podatki ali utemeljitev, ki pa so bili za odbor CHMP nezadostni, da bi lahko ugotovili biološko enakovrednost z referenčnim zdravilom, odobrenim v EU;
An authorised medicinal product may be considered critical by the EU Member States based on the evaluation of the potential unmet medical need, considering the availability of suitable alternative medicinal products in the respective EU Member States and, as appropriate, the nature of the disease to be treated. 
Odobreno zdravilo se lahko šteje za zdravilo kritičnega pomena v posamezni državi članici EU na podlagi ocene morebitnih neizpolnjenih zdravstvenih potreb ter ob upoštevanju razpoložljivosti ustreznih drugih možnih zdravil v zadevni državi članici EU in, če je primerno, narave zdravljene bolezni.
For the suspension of the marketing authorisations to be lifted the MAH shall demonstrate bioequivalence data vis-à-vis a valid EU reference medicinal product based on relevant data, in accordance with the requirements of Article 10 of Directive 2001/83/EC (e.g. a bioequivalence study conducted vis-à-vis the EU reference medicinal product). 
Za preklic začasnega umika dovoljenj za promet z zdravilom morajo imetniki dovoljenj za promet z zdravilom predložiti podatke o biološki enakovrednosti z veljavnim referenčnim zdravilom, odobrenim v EU, na podlagi ustreznih podatkov, v skladu z zahtevami člena 10 Direktive 2001/83/ES (npr. študijo biološke enakovrednosti, opravljeno glede na referenčno zdravilo, odobreno v EU).
For all other marketing authorisation applications subject to this referral the CHMP considers that the applicants did not submit information which allows establishing bioequivalence to the EU reference medicinal product, and therefore the marketing authorisation applications do not currently fulfil the criteria for authorisation. 
Kar zadeva vse druge vloge za pridobitev dovoljenja za promet z zdravilom, na katere se nanaša ta napotitev, je odbor CHMP menil, da predlagatelji niso dokazali biološke enakovrednosti z referenčnim zdravilom, odobrenim v EU, zato trenutno vloge za pridobitev dovoljenja za promet z zdravili ne izpolnjujejo meril za pridobitev dovoljenja.
• The Committee concluded that the particulars supporting the marketing authorisations and marketing authorisation applications are incorrect and that the benefit-risk balance is considered not favourable for: 
• odbor je zaključil, da podatki, ki podpirajo dovoljenja za promet z zdravilom/vloge za pridobitev dovoljenja za promet z zdravilom, niso ustrezni in da razmerje med tveganji in koristmi ni ugodno za:
For these medicinal products considered critical by EU Member State(s), the marketing authorisations holders shall submit a bioequivalence study conducted vis-à-vis the EU Reference Medicinal Product within 12 months from the Commission Decision. 
Za ta zdravila, ki jih ena ali več držav članic šteje za zdravila kritičnega pomena, imetniki dovoljenj za promet z zdravilom v 12 mesecih od izdaje sklepa Komisije predložijo študijo biološke enakovrednosti, opravljeno glede na referenčno zdravilo, odobreno v EU.
c. Marketing authorisations for medicinal products for which the bioequivalence vis-à-vis the EU reference medicinal product has been established should be maintained, as the benefit risk balance of these marketing authorisation is considered favourable. 
c. Dovoljenja za promet z zdravilom, za katera je bila ugotovljena biološka enakovrednost z referenčnim zdravilom, odobrenim v EU, naj se ohranijo, saj je razmerje med tveganji in koristmi za ta dovoljenja za promet z zdravilom ugodno.
b. Marketing authorisation applications for which data or justification were not submitted or considered insufficient by the CHMP to establish bioequivalence vis-à-vis the EU reference medicinal product do not satisfy the criteria for authorisation, as the particulars supporting the marketing authorisations are incorrect and the benefit-risk balance of these marketing authorisation is considered not favourable pursuant to Article 26 of Directive 2001/83/EC. 
b. Vloge za pridobitev dovoljenja za promet z zdravilom, za katere podatki ali njena utemeljitev niso bili predloženi oziroma za katera je odbor CHMP menil, da ne zadostujejo za ugotovitev biološke enakovrednosti z referenčnim zdravilom, odobrenim v EU, ne izpolnjujejo meril za pridobitev dovoljenja, saj podatki v podporo dovoljenjem za promet niso ustrezni in razmerje med tveganji in koristmi teh dovoljenj za promet z zdravilom v skladu s členom 26 Direktive 2001/83/ES ni ugodno.
• The Committee concluded that, for both marketing authorisations and marketing authorisation applications where there was alternative data to establish bioequivalence vis-à-vis the EU reference medicinal product the benefit-risk balance is considered favourable. 
• odbor je zaključil, da je razmerje med tveganji in koristmi za dovoljenja za promet z zdravilom in vloge za pridobitev dovoljenja za promet z zdravilom, za katere so bili predloženi drugi možni podatki za dokaz biološke enakovrednosti z referenčnim zdravilom, odobrenim v EU, ugodno,
Should during this period the EU Member State(s) consider a medicinal product not critical anymore, the suspension of the concerned marketing authorisation shall apply. 
Če v tem obdobju ena ali več držav članic EU zdravila ne šteje več za zdravilo kritičnega pomena, je treba uveljaviti začasen umik zadevnega dovoljenja za promet z zdravilom.
Some of these authorised medicinal products may be considered critical by the individual EU Member States on the evaluation of the potential unmet medical need, considering the availability of suitable alternative medicinal products in the respective EU Member State(s) and, as appropriate, the nature of the disease to be treated. 
Nekatera od teh zdravil se lahko na podlagi ocene morebitnih neizpolnjenih zdravstvenih potreb in ob upoštevanju razpoložljivosti ustreznih drugih možnih zdravil v eni ali več zadevnih državah članicah EU ter, če je primerno, narave zdravljene bolezni, štejejo za zdravila kritičnega pomena v posamezni državi članici.
Bioequivalence (BE) is required for the conclusion that efficacy and safety are similar to those of the reference medicinal product for a medicinal product with a marketing authorisation or marketing authorisation application under Article 10(1) of Directive 2001/83/EC. 
Za zaključek o podobni učinkovitosti in varnosti zdravila z dovoljenjem za promet ali vlogo za pridobitev dovoljenja za promet v primerjavi z referenčnim zdravilom je treba v skladu s členom 10(1) Direktive 2001/83/ES opraviti študijo biološke enakovrednosti.
Therefore, in accordance with Articles 31 and 32 of Directive 2001/83/EC, the CHMP concludes that: a. Marketing authorisations for medicinal products for which bioequivalence data or justification were not submitted or considered insufficient by the CHMP to establish bioequivalence vis-à-vis the EU reference medicinal product should be suspended, as the particulars supporting the marketing authorisations are incorrect and the benefit-risk balance of these marketing authorisation is considered not favourable pursuant to Article 116 of Directive 2001/83/EC. 
a. Dovoljenja za promet z zdravili, za katera niso bili predloženi podatki o biološki enakovrednost ali njena utemeljitev oziroma za katera je odbor CHMP menil, da zadevni podatki ne zadostujejo za ugotovitev biološke enakovrednosti z referenčnim zdravilom, odobrenim v EU, naj se začasno umaknejo, saj podatki v podporo dovoljenjem za promet niso ustrezni in razmerje med tveganji in koristmi za ta dovoljenja za promet z zdravili v skladu s členom 116 Direktive 2001/83/ES ni ugodno.
Invented name Strength Pharmaceutical Form Route of Administration Packaging 
Številka EU Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina velikost pakiranja
Week 1 Week 2 Week 3 Week 4 
Teden 1 Teden 2 Teden 3 Teden 4
To benefit from your medicine you should take it regularly every day at the same time of the day. 
Da bi vam zdravilo koristilo, ga morate jemati redno vsak dan ob istem času .
Once daily. 
Enkrat dnevno.
Ergates Industrial Area, 2643 Nicosia Cyprus 
Ergates Industrial Area, 2643 Nicosia Ciper
Some factors that may raise urine pH (see section 5.2 'Elimination') may necessitate careful monitoring of the patient. 
Zaradi nekaterih dejavnikov, ki lahko povišajo pH urina (glejte poglavje 5.2 »Izločanje«) je potreben skrben nadzor bolnika.
1 Hallucinations have mainly been observed in patients with severe Alzheimer's disease. 
1 Halucinacije so bile večinoma opažene pri bolnikih s hudo Alzheimerjevo boleznijo.
The tablets should be swallowed with a little water. 
Tablete pogoltnite z manjšo količino vode.
Memantine Accord is not recommended for children and adolescents under the age of 18 years. 
Zdravila Memantin Accord ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
Adverse reactions are ranked according to system organ class, using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjih navedb: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Memantine is eliminated in a monoexponential manner with a terminal t½ of 60-100hours. 
Memantin se izloča na monoekspotencialni način s končnim razpolovnim časom (t½) 60 do 100 ur.
Date of latest renewal: 3rd August 2018 
Datum zadnjega podaljšanja: 3. avgusta 2018
Memantine Accord should be administered once a day and should be taken at the same time every day.The film-coated tablets can be taken with or without food. 
Zdravilo Memantin Accord je treba dajati enkrat dnevno in ob istem času vsak dan. Filmsko obložene tablete lahko jemljete s hrano ali brez.
Your doctor will advise you. 
Zdravnik vam bo svetoval, kaj storiti.